PT - JOURNAL ARTICLE AU - Daniel Stamate AU - Min Kim AU - Petroula Proitsi AU - Sarah Westwood AU - Alison Baird AU - Alejo Nevado-Holgado AU - Abdul Hye AU - Isabelle Bos AU - Stephanie Vos AU - Rik Vandenberghe AU - Charlotte E. Teunissen AU - Mara Ten Kate AU - Philip Scheltens AU - Silvy Gabel AU - Karen Meersmans AU - Olivier Blin AU - Jill Richardson AU - Ellen De Roeck AU - Sebastiaan Engelborghs AU - Kristel Sleegers AU - Régis Bordet AU - Lorena Rami AU - Petronella Kettunen AU - Magda Tsolaki AU - Frans Verhey AU - Daniel Alcolea AU - Alberto Lléo AU - Gwendoline Peyratout AU - Mikel Tainta AU - Peter Johannsen AU - Yvonne Freund-Levi AU - Lutz Frölich AU - Valerija Dobricic AU - Giovanni B Frisoni AU - José L Molinuevo AU - Anders Wallin AU - Julius Popp AU - Pablo Martinez-Lage AU - Lars Bertram AU - Kaj Blennow AU - Henrik Zetterberg AU - Johannes Streffer AU - Pieter J Visser AU - Simon Lovestone AU - Cristina Legido-Quigley TI - A metabolite-based machine learning approach to diagnose Alzheimer’s-type dementia in blood: Results from the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort AID - 10.1101/19007146 DP - 2019 Jan 01 TA - medRxiv PG - 19007146 4099 - http://medrxiv.org/content/early/2019/09/27/19007146.short 4100 - http://medrxiv.org/content/early/2019/09/27/19007146.full AB - INTRODUCTION Machine learning (ML) may harbor the potential to capture the metabolic complexity in Alzheimer’s Disease (AD). Here we set out to test the performance of metabolites in blood to categorise AD when compared to CSF biomarkers.METHODS This study analysed samples from 242 cognitively normal (CN) people and 115 with AD-type dementia utilizing plasma metabolites (n=883). Deep Learning (DL), Extreme Gradient Boosting (XGBoost) and Random Forest (RF) were used to differentiate AD from CN. These models were internally validated using Nested Cross Validation (NCV).RESULTS On the test data, DL produced the AUC of 0.85 (0.80-0.89), XGBoost produced 0.88 (0.86-0.89) and RF produced 0.85 (0.83-0.87). By comparison, CSF measures of amyloid, p-tau and t-tau (together with age and gender) produced with XGBoost the AUC values of 0.78, 0.83 and 0.87, respectively.DISCUSSION This study showed that plasma metabolites have the potential to match the AUC of well-established AD CSF biomarkers in a relatively small cohort. Further studies in independent cohorts are needed to validate whether this specific panel of blood metabolites can separate AD from controls, and how specific it is for AD as compared with other neurodegenerative disordersCompeting Interest StatementThe authors have declared no competing interest.Funding StatementIMI hasAuthor DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesOn request to the data repository’s